Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $22.8550 (0.33%) ($22.8550 - $22.8550) on Wed. Jan. 13, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3% (three month average) | RSI | 36 | Latest Price | $22.8550(0.33%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -0.6% a day on average for past five trading days. | Weekly Trend | FOLD declines -1.4% a week on average for past two weeks. | Market Behavior | Growth stock rally for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(53%) IWO(50%) XBI(48%) IWM(47%) IWC(44%) | Factors Impacting FOLD price | FOLD will decline at least -1.5% in a week (0% probabilities). VIXM(-29%) VXX(-14%) UUP(-11%) UNG(-6%) TLT(-1%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.5% (StdDev 3%) | Hourly BBV | 0.7 () | Intraday Trend | 0% | | | |
|
Resistance Level | $23.36 | 5 Day Moving Average | $23.07(-0.93%) | 10 Day Moving Average | $22.88(-0.11%) | 20 Day Moving Average | $23.36(-2.16%) | To recent high | -8.2% | To recent low | 39.5% | Market Cap | $5.902b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |